Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy: A randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine

Volumn 134, Issue 4, 2001, Pages

  Weissman, N J ^a   Panza, J A ^a   Tighe J F , Jr ^a   Gwynne, J T ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; PLACEBO;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MULTICENTER STUDY; OBESITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VALVULAR HEART DISEASE;

ADULT; ANALYSIS OF VARIANCE; AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; DEXFENFLURAMINE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; OBESITY; PLACEBOS; SEROTONIN AGONISTS; STATISTICS, NONPARAMETRIC;

EID: 0035916262     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Valvular heart disease associated with fenfluramine-phentermine
2. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
3. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine
4. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
5. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities
6. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo
7. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997
8. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment
9. Color Doppler assessment of mitral regurgitation with orthogonal planes
10. Evaluation of aortic insufficiency by Doppler color flow mapping
11. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation
12. Weighted κ: Nominal scale agreement with provision for scaled disagreement or partial credit
13. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication
14. Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment
15. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine
16. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine
17. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months